Feature article: Automation solutions for single-use bioreactors

10. January 2023 by Andreas Pompenig Automation, Biotech, Feature article, Single Use Technology

Integrating Single-Use Systems: ZETA's Automation Expertise

As a leading supplier of customized automation solutions for biopharmaceutical production processes, ZETA seamlessly integrates single-use systems into new or existing automation environments. A landmark project for a major international pharmaceutical company was the starting point for a series of follow-up projects in Switzerland and Germany.

Highest customer satisfaction

The original fast-track project involved the integration and automation of four single-use bioreactors supplied by Cytiva. It included the engineering, manufacturing, and installation of a stainless-steel work platform with utility supply piping for the clean rooms. The customer was highly satisfied and contracted ZETA to supply a second production line.

Integrating Single-Use Systems: ZETA's Automation Expertise.


Find out more about our innovative solutions and optimizations in the follow-up projects!



Whitepaper Download

Contact Maximilian van de Graaf - Head of Sales Automation
Contact: Maximilian van de Graaf
Head of Sales

Our expert is looking forward
to hearing from you!

Related Posts

Feature Article: Cybersecurity in the OT Environment of Pharmaceutical Production Plants
Press Release: Rockwell Automation Welcomes ZETA as EPC Partner
Review: ZETA Symposium 2024
Press Release: ZETA Group acquires SIGMA to boost pharmaceutical automation
Feature Article: Production simulation for planning and operation
Feature Article: Virus inactivation with UV light


Erhalten Sie interessante Themen aus dem Blog als Newsletter!

The digital assistant from ZETA.
Digital Assistant
  • Last
    search queries
  • Last
  • Last
    blog posts
The digital assistant from ZETA.
Your ZETA Digital Assistant

Welcome back!

Recently viewed

No results

You have no results yet.

Maybe also interesting

No results

You have no results yet.